Zimmer Biomet beats profit estimates on strong demand for medical devices
Aug 7 (Reuters) -Zimmer Biomet Holdings ZBH.N beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for its devices used in joint reconstruction procedures.
Medical device makers have boosted investor expectations in the recent quarters as more people, especially older Americans, opt for non-urgent surgeries such as hip and knee replacements.
Peer Stryker Corp SYK.N last month raised its annual profit outlook betting on robust demand for its hip and knee implants.
Zimmer, however, cut its annual revenue growth forecast anticipating a higher foreign currency impact. Zimmer now sees revenue growth of 4% to 5% from a year earlier, compared to 4.5% to 5.5% growth forecast previously.
Combined sales at Zimmer's hips and knees units came in at $1.31 billion, shy of analysts' estimate of $1.32 billion, according to LSEG data.
The company also saw strong sales at its unit that sells sports medicine and trauma care products. Sales at the unit rose 6.1% year-over-year to $469.5 million, topping estimates of $465.4 million.
Separately, Zimmer said on Tuesday it would acquire OrthoGrid Systems, a privately held medtech firm to gain access to its artificial intelligence-driven surgical guidance systems for total hip replacement.
The hip and knee implant maker reiterated its full-year 2024 profit expectations in the range of $8.00 to $8.15 per share. Analysts were expecting annual profit of $8.09 per share.
Zimmer's second-quarter revenue rose nearly 4% to $1.94 billion, in-line with analysts' average estimates.
On an adjusted basis, the company posted a profit of $2.01 per share in the quarter ended June 30, topping estimates of $1.99 per share.
Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
